Showing posts with label Pfizer. Show all posts
Showing posts with label Pfizer. Show all posts

Sunday 30 December 2018

Pediatric Vacciness Market Likely To Reach A Valuation Of Around USD 60.4 Billion By 2025:Key Participant GlaxoSmithKline plc, Pfizer, Inc.


San Francisco, 31 December 2018,  Pediatric Vaccines Market Analysis By Type (Monovalent, Multivalent), By Technology (Live Attenuated, Inactivated, Subunit, Toxoid, Conjugate), By Application (Infectious Diseases, Cancer, Allergy), By Region, And Segment Forecasts, 2018 – 2025
The global pediatric vaccines market is expected to reach USD 60.4 billion by 2025 at an 11.7% CAGR, according to a new report by Grand View Research, Inc. Advancements in development of vaccines and new product launches are some of the major drivers of the market. 
Increase in investments by companies to capture a larger market share is anticipated to propel growth. Some of the factors attributed to increase in investment are high growth prospects in the emerging market, immunization schedule mandated by doctors for children, and awareness programs led by UNICEF, WHO, and other healthcare organizations. Furthermore, increase in number of government initiatives for raising awareness about immunization is expected to boost the market for pediatric vaccines.
Advancements in development of novel adjuvants and therapeutic vaccines are expected to drive growth during the forecast period. Ongoing research in novel molecules targeted at specific mechanisms of action in the body is aimed at providing immunity against fatal diseases such as cancer and Zika virus disease. For instance, in June 2016, Inovio Pharmaceuticals, Inc. announced the initiation of phase I clinical trial for their Zika DNA vaccine named GLS-5700.
Access Full Research Report On Pediatric Vaccines Market  Analysis:
www.grandviewresearch.com/industry-analysis/pediatric-vaccine-market
Further key findings from the report suggest:
·         The global pediatric vaccines market was estimated at USD 22.4 billion in 2016 and is expected to grow with a CAGR of 11.7% from 2017 to 2025
·         By type, monovalent emerged as the largest segment due to factors such as high usage and increase in initiatives for R&D activities supported by various governments
·         Conjugate vaccines formed the dominant technology segment in terms of revenue in 2016. Higher adoption of these vaccines and increase in prevalence of infectious diseases contribute to its lead in the market for pediatric vaccines
·         By application, the cancer segment is expected to witness the fastest growth with a CAGR of 12.6% owing to increasing prevalence of cancer and rising need for immunization against the disease
·         North America held the largest revenue share in 2016. Its dominance in the market for pediatric vaccines is owing to factors such as local presence of major players in the industry and extensive R&D activities
·         The Asia Pacific region is anticipated to witness lucrative growth over the next decade due to increase in prevalence of infectious diseases and a large target population
·         Key players such as GlaxoSmithKline plc; Pfizer, Inc.; SANOFI; and AstraZeneca dominated the global market for pediatric vaccines in 2016.
Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global pediatric vaccines market on the basis of type, technology, application, and region:
Type Outlook (Market Revenue in USD Billion, 2014 - 2025)
·         Monovalent
·         Multivalent
Technology Outlook (Market Revenue in USD Billion, 2014 - 2025)
·         Live Attenuated
·         Inactivated
·         Subunit
·         Toxoid
·         Conjugate
·         Others
Application Outlook (Market Revenue in USD Billion, 2014 - 2025)
·         Infectious disease
·         Cancer
·         Allergy
Regional Outlook (Revenue, USD Billion, 2014 - 2025)
·         North America
o    U.S.
o    Canada
·         Europe
o    Germany
o    U.K.
·         Asia Pacific
o    China
o    Japan
o    India
·         Latin America
o    Brazil
o    Mexico
·         Middle East & Africa
o    South Africa

Access Full Press Release of this Report:

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/





Tuesday 25 December 2018

PCOS Treatment Market Expected To Trigger A Revenue Increase To USD 5.1 Billion By 2025:Key Participant AstraZeneca, Bayer AG


San Francisco, 24 December 2018,  Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-obesity), By Surgery, And Segment Forecasts, 2018 - 2025

The global polycystic ovarian syndrome treatment market is expected to reach USD 5.1 billion by 2025, according to a new report by Grand View Research, Inc. According to the Centers of Disease Control & Prevention (CDC), Polycystic Ovary Syndrome (PCOS) is the most common cause of female infertility. Approximately 6% to 12% women of reproductive age suffer from PCOS in the U. S. Moreover, progression of this condition can lead to metabolic abnormalities, which may result in development of type 2 diabetes, if the syndrome is not treated on time. The severity of the disorder increases the risk of developing uterine and endometrial cancers in patients. Thus, early diagnosis and effective treatment are significant for successful recovery. 
Presently, no specific drug is commercially available for this condition. Thus, treating symptoms is the prime aim of the treatment regimen. Owing to the various symptoms associated with this syndrome, a range of drug class/combinations is used in the treatment. Therefore, market leaders are focusing on developing a specific drug/treatment to cure the root cause of this disease. AstraZeneca is one of the leaders involved in developing such a drug.
Access Full Research Report On Polycystic Ovarian Syndrome (PCOS) Treatment Market  Analysis:

Further Key Findings from the Study Suggest:
·         Constantly rising prevalence of PCOS is primarily driving the growth of this market across the globe
·         Initiatives undertaken by government bodies and market players to create awareness about benefits of early diagnosis and commercially available treatment for PCOS among women is boosting the market
·         Treatment of PCOS mainly includes lifestyle modification through balanced diet, exercise, and drugs such as oral contraceptives, antiandrogens, insulin-sensitizing agents, anti-obesity agents, and antidepressants
·         Surgical procedures such as ovarian wedge resection and laparoscopic ovarian drilling are preferred when patients do not respond to drug therapy
·         Insulin-sensitizing agents segment is dominating the market since these drugs are widely used for treatment of insulin resistance to prevent diabetes, which is a risk associated with PCOS
·         Oral Contraceptive Pills (OCPs) segment is expected to grow at the fastest rate followed by antiandrogen agents that are used for treating symptomatic conditions such as hirsutism and acne
·         North America is dominating the market followed by Europe. High awareness and availability of advanced healthcare facilities are factors responsible for the dominant share held by this region
·         Asia Pacific is expected to be the fastest growing region over the forecast period.Increasing government initiatives for raising awareness about symptoms & diagnosis of PCOS and available treatment are increasing the number of women being diagnosed with this syndrome in the region
·         China is one of the most lucrative markets with tremendous growth opportunities for global as well as local players owing to presence of a large pool of obese female population, which is at high risk of PCOS
·         Key players in the market include AstraZeneca, Bayer AG, Merck KGaA, Abbott, Sanofi, Pfizer, Inc., Bristol-Myer Squibb Company, and Novartis AG. The market also includes other emerging players such as Teva Pharmaceutical Industries Limited and Ferring Pharmaceuticals, Inc., which are expected to grow significantly in the near future.
Browse More Reports Of This Category By Grand View Research At:   www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the PCOS treatment market on the basis of drug class, surgery type, and region:
Drug Class Outlook (Revenue, USD Billion; 2014 - 2025)
·         Oral Contraceptives
·         Antiandrogens
·         Insulin Sensitizing Agent
·         Antidepressant
·         Anti-obesity
Surgery Outlook (Revenue, USD Billion; 2014 - 2025)
·         Ovarian Wedge Resection
·         Laparoscopic Ovarian Drilling
Regional Outlook (Revenue, USD Billion; 2014 - 2025)
·         North America
o    U.S.
o    Canada
·         Europe
o    Germany
o    UK
·         Asia Pacific
o    China
o    Japan
·         Latin America
o    Mexico
o    Brazil
·         MEA
o    South Africa


About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/


Friday 26 October 2018

Hormonal Contraceptive Market Is To Reach A Value Of $26.2 Billion Forecast Till 2025: Grand View Research, Inc.


The global hormonal contraceptive market size is expected to reach USD 26.2 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 4.0% during the forecast period. Introduction of innovative products in the market and growing awareness about reproductive and sexual health in emerging regions are likely to drive the market in the coming years.
Pill, Intrauterine Devices (IUD), injectable, vaginal rings, implants, and patches are various methods used for hormonal contraception. Hormonal contraception methods act on the endocrine system to prevent ovulation.
Increasing number of women in developing economies are using contraceptives due to rise in government initiatives and programs, which is anticipated to accelerate market growth. For instance, according to the UN, approximately 64.0% of women between 15 and 49 years of age were using some form of family planning in 2015, be it traditional or modern. This figure stood at 36.0% in 1970.
The number of unintended pregnancies annually is highest in U.S., which is about 3 million. Hence, the Center for Medicaid and CHIP Services (CMCS) established a Maternal and Infant Health Initiative for the Medicaid and Children’s Health Insurance Program (CHIP) program to promote use of effective methods of contraception and help women avoid such pregnancies.
Browse Research Report on Hormonal Contraceptive Market:

Further key findings from the report suggest:

·         Increasing demand for contraceptive methods can be attributed to growing awareness about pills and devices, increasing significance of family planning, and supportive government regulations improving access to these products
·         In 2016, pills accounted for the largest share in the market as they are convenient to use and exhibit more than 99.0% effectivity when accurately consumed. Furthermore, ease of availability, fewer adverse effects, and large number of players operating in the market can be attributed to this share
·         The IUD segment is expected to witness the fastest growth during the forecast period. This can be attributed to entry of new devices in the market over the recent past, availability of long-acting reversible birth control methods, and more than 99.0% effectivity
·         Geographically, North America held the largest share in 2016 and is anticipated to maintain its dominance during the forecast period due to local presence of market players, high per capita income, and supportive government initiatives
·         Asia Pacific is estimated to witness the fastest growth during the forecast period due to high unmet need, expected increase in coverage during the next 15 years, and increasing number of women of reproductive age
·         Some of the key players operating in the market are Teva Pharmaceuticals Industries Ltd.; Bayer AG, Merck & Co. Inc.; Pfizer, Afaxys, Inc.; Agile Therapeutics; Allergan; and Apothecus Pharmaceutical Corporation.

View more reports of this category by Grand View Research at
Grand View Research has segmented the global hormonal contraceptive market on the basis of method and region:
Hormonal Contraceptive Method Outlook (Revenue, USD Million, 2014 - 2025)
·         Pill
·         Intrauterine Devices (IUD)
·         Injectable
·         Vaginal Ring
·         Implant
·         Patch
View press release of this research report by Grand View Research:

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and healthcare.
For more information: www.grandviewresearch.com